TIGIT and PD-L1 co-blockade promotes dendritic cell-dependent production of non-exhausted CD8+ T cells
Immunity · 2026-11 · 59 (11) · 3061-3080.e8
DOI: 10.1016/j.immuni.2026.10.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2026-11. Verfasst von Ellen Duong und 24 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Receptors, Immunologic, B7-H1 Antigen, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 101 Literaturangaben.
Abstract (Originalsprache)
Combination immunotherapy targeting the coinhibitory molecules TIGIT and PD-L1 promotes non-exhausted CD8+ T cell differentiation in cancer. Because anti-TIGIT efficacy requires Fc binding, we investigated the role of Fcγ receptor (FcγR)-expressing myeloid cells in the mechanism of action. Conventional dendritic cells (cDCs) were required for therapeutic efficacy. Transcriptional profiling of intratumoral myeloid cells revealed an FcγR+ cDC type-1 (cDC1)-like activation state characterized by elevated costimulatory ligands for CD28 (CD80/CD86) and CD226 (PVR) that was enriched in Fc-active anti-TIGIT combination-treated tumors. Therapy-expanded CD8+ T cells expressed CD28 and upregulated CD226 upon treatment. Mechanistically, CD28 signaling was a prerequisite for therapy-induced CD226 expression on T cells, and cDC-derived PVR promoted CD226-mediated non-exhausted T cell differentiation. Type I interferon (IFN-I), induced through FcγR engagement, maintained and amplified the FcγR+ cDC1-like state, and exogenous IFN-I rescued anti-tumor immunity upon Fc-inert anti-TIGIT and anti-PD-L1 combination. Thus, Fc-active anti-TIGIT and anti-PD-L1 therapy promotes a sequential costimulatory cascade centered on cDCs, amplified by IFN-I signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genentech, South San Francisco, CA, USA.
- Genentech, South San Francisco, CA, USA. Electronic address: ohs5@gene.com.
- Genentech, South San Francisco, CA, USA. Electronic address: imellman@parkerici.org.
Zitieren
APA
Duong, E., Wu, T. D., Tran, C. W., Foo, C., Banta, K. L., Adams, L., Nutsch, K., Anand, A. A., Carbone, C. B., Gutierrez, A., Chestnut, Y., Balança, C. C., Tomaszewski, W. H., Andrusivová, Ž., Jiang, J., Antonelli, A. C., Decalf, J., Cheung, J., Luoh, S. M., …, & Mellman, I. (2026). TIGIT and PD-L1 co-blockade promotes dendritic cell-dependent production of non-exhausted CD8+ T cells. Immunity, 59(11), 3061-3080.e8. https://doi.org/10.1016/j.immuni.2026.10.005
Vancouver
Duong E, Wu TD, Tran CW, Foo C, Banta KL, Adams L, et al. TIGIT and PD-L1 co-blockade promotes dendritic cell-dependent production of non-exhausted CD8+ T cells. Immunity. 2026;59(11):3061-3080.e8. doi:10.1016/j.immuni.2026.10.005
BibTeX
@article{Duong2026,
author = {Duong, Ellen and Wu, Thomas D and Tran, Charles W and Foo, Conrad and Banta, Karl L and Adams, Lili and Nutsch, Katherine and Anand, Aditya A and Carbone, Catherine B and Gutierrez, Alan and Chestnut, Yajun and Balança, Camille-Charlotte and Tomaszewski, William H and Andrusivová, Žaneta and Jiang, Jian and Antonelli, Anthony C and Decalf, Jérémie and Cheung, Jeanne and Luoh, Shiuh-Ming and Rost, Sandra and McGinnis, Lisa M and Hornburg, Milena and Chiang, Eugene Y and Oh, Soyoung A and Mellman, Ira},
title = {TIGIT and PD-L1 co-blockade promotes dendritic cell-dependent production of non-exhausted CD8+ T cells},
journal = {Immunity},
year = {2026},
volume = {59},
number = {11},
pages = {3061--3080.e8},
doi = {10.1016/j.immuni.2026.10.005}
}
EUVIMED